Navigation Links
SeqWright's Clinical Trial Support Contributes to the Approval of Two HPV Diagnostic Systems
Date:4/7/2009

HOUSTON, April 7 /PRNewswire/ -- SeqWright Inc., an international leader in the field of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human Papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to validate two Hologic HPV diagnostic tests; Cervista HPV High Risk (HR) and Cervista HPV 16/18, in preparation for FDA submission. Both tests were recently awarded FDA premarket approval. According to Hologic, their Cervista HPV HR clinical trial involved over 4,000 women spread across 89 sites throughout the United States and constituted one of the largest and most demographically diverse clinical trials ever conducted in the United States.

SeqWright was selected to perform the sequencing-based validations of Hologic's HPV Diagnostics assays after successfully completing several of Hologic's previous clinical trials, which all led to FDA approvals. SeqWright maintains advanced quality control with a Clinical Laboratory Improvement Amendment (CLIA) certification as well as maintaining compliance with Good Laboratory Practices (GLPs) as specified in the Code of Federal Regulations.

Sequencing for Hologic's clinical trials was performed under GLP guidelines (4X-bidirectional sequencing, stringent controls, full documentation) and all samples were continuously tracked and monitored. The bioinformatics provided by SeqWright were also vital to trial success and were used to implement Hologic's HPV genotyping analysis as well as to create a customized clinical trial decision tree algorithm. These services led to a streamlined, reliable and efficient testing regimen in support of Hologic's two recently approved HPV Diagnostics.

SeqWright CEO, Dr. Fei Lu, M.D. stated, "We wish to congratulate Hologic on the pre-market approvals of their new HPV diagnostic tests and we are proud of the work we performed in support of their efforts."

About SeqWright:

SeqWright Incorporated is a world-class genomic services support organization based in Houston, TX with more than fifteen years of experience specializing in state of the art Molecular Biology and Genomic services within a highly regulated GLP/CLIA environment. For additional information about SeqWright and its services, please visit www.seqwright.com.


'/>"/>
SOURCE SeqWright Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , 12 februari 2016 ... een toonaangevende leverancier van productie en ontwikkeling ... industrieën, kondigt vandaag een uitbreiding aan van ... haar locatie in Charleston, SC ... geleid tot meerdere recente investeringen. ...
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... 11, 2016  Walgreens has committed to provide drug ... Washington, D.C. as part of a ... commended by shareholder advocacy organization As You Sow. ... "Many people hold on to unneeded drugs because they lack ... consequences." --> Conrad MacKerron , Senior Vice ...
Breaking Medicine Technology:
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn ... 2015 will show what to expect when they come knocking this year. But that takes ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical Therapy Association ... CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the country are ... action, learn more about their chosen field and network with their colleagues. As ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker ... Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and ... hydrated before the big event. The invitation-only gifting suite, held this year at the ...
(Date:2/12/2016)... Appleton, Wis. (PRWEB) , ... February 12, 2016 ... ... its second Lean Leadership Series at Zuckerberg San Francisco General Hospital on April ... to practice new behaviors and create new habits. The workshops cover a broad ...
Breaking Medicine News(10 mins):